Ceforanide (BioDeep_00000006366)

 

Secondary id: BioDeep_00001868221

human metabolite blood metabolite


代谢物信息卡片


(6R,7R)-7-{2-[2-(aminomethyl)phenyl]acetamido}-3-({[1-(carboxymethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

化学式: C20H21N7O6S2 (519.0995)
中文名称: 头孢氨酯
谱图信息: 最多检出来源 Homo sapiens(blood) 50%

分子结构信息

SMILES: C1C(=C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O
InChI: InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1

描述信息

Ceforanide is a second-generation parenteral cephalosporin antibiotic. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DC - Second-generation cephalosporins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

同义名列表

30 个代谢物同义名

(6R,7R)-7-{2-[2-(aminomethyl)phenyl]acetamido}-3-({[1-(carboxymethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulphanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulphanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulphanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; 7beta-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; 7Β-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulphanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; 7b-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulphanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; 7b-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; 7beta-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulphanyl}methyl-3,4-didehydrocepham-4-carboxylate; 7Β-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid; 7beta-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylate; 7Β-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulphanyl}methyl-3,4-didehydrocepham-4-carboxylate; 7b-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulphanyl}methyl-3,4-didehydrocepham-4-carboxylate; 7b-[2-(Aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylate; 7Β-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylate; 7-[O-(Aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; 7-(alpha-(2-Aminomethylphenyl)acetamido)-3-((1-carboxymethyltetrazol-5-ylthio)methyl)-3-cephem-4-carboxylic acid; 7-[O-(Aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylate; Ceforanide, monosodium salt; SCHEMBL14303761; Ceforanidum; Ceforanido; Cefaronide; Ceforanide; BL-S786R; BL-S 786; Precef; Ceforanide



数据库引用编号

17 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

2 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Stavros Sifakis, Emmanuel Angelakis, Antonis Makrigiannakis, Irene Orfanoudaki, Maria Christakis-Hampsas, Pavlos Katonis, Aristidis Tsatsakis, Eugenios Koumantakis. Chemoprophylactic and bactericidal efficacy of 80 mg gentamicin in a single and once-daily dosing. Archives of gynecology and obstetrics. 2005 Sep; 272(3):201-6. doi: 10.1007/s00404-004-0698-7. [PMID: 15605270]
  • David G Levitt. The pharmacokinetics of the interstitial space in humans. BMC clinical pharmacology. 2003 Jul; 3(?):3. doi: 10.1186/1472-6904-3-3. [PMID: 12890292]
  • P F Souney, S Fisher, R E Tuomala, B F Polk, C Simpson. Plasma and tissue concentrations of ceforanide and cefazolin in women undergoing hysterectomy. Chemotherapy. 1988; 34(3):185-90. doi: 10.1159/000238569. [PMID: 3416659]
  • R Soave, J C Hirsch, E A Salvati, B D Brause, R B Roberts. Comparison of ceforanide and cephalothin prophylaxis in patients undergoing total joint arthroplasty. Orthopedics. 1986 Dec; 9(12):1657-60. doi: 10.3928/0147-7447-19861201-08. [PMID: 3547369]
  • J M Lanao, C R de Prada, A Dominguez-Gil, J M Tabernero, J Martín, J R Gómez. Ceforanide pharmacokinetics in haemodialysis: the effect of ultrafiltration. Biopharmaceutics & drug disposition. 1986 Jul; 7(4):335-46. doi: 10.1002/bdd.2510070404. [PMID: 3768489]
  • A L Barry, R N Jones, R R Packer. Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum. Antimicrobial agents and chemotherapy. 1986 Jan; 29(1):147-9. doi: 10.1128/aac.29.1.147. [PMID: 3729326]
  • L D Saravolatz, C Lee, B Drukker. Comparison of intravenous administration with intrauterine irrigation with ceforanide for nonelective cesarean section. Obstetrics and gynecology. 1985 Oct; 66(4):513-6. doi: . [PMID: 3900837]
  • V H Guerrini, L J Filippich, G R Cao, P B English, D W Bourne. Pharmacokinetics of cefaronide, ceftriaxone and cefoperazone in sheep. Journal of veterinary pharmacology and therapeutics. 1985 Jun; 8(2):120-7. doi: 10.1111/j.1365-2885.1985.tb00935.x. [PMID: 4020943]
  • J T DiPiro, S M Bayoumi, J J Vallner, R R Nesbit, R Gokhale, J P Rissing. Intraoperative ceforanide pharmacokinetics and protein binding. Antimicrobial agents and chemotherapy. 1985 Apr; 27(4):487-90. doi: 10.1128/aac.27.4.487. [PMID: 4004190]
  • R Platt, B Rosner. Effect of hydrogen ion and protein concentrations on the activity of beta-lactam antibiotics. Reviews of infectious diseases. 1984 Nov; 6 Suppl 4(?):S829-34. doi: 10.1093/clinids/6.supplement_4.s829. [PMID: 6522925]
  • J L Lefrock, W Holloway, B B Carr, R F Schell. In vitro and clinical evaluation of ceforanide. The American journal of the medical sciences. 1984 Mar; 287(2):21-5. doi: 10.1097/00000441-198403000-00005. [PMID: 6711584]
  • R L Greenman, S M Arcey, D A Gutterman, R M Zweig. Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers. Antimicrobial agents and chemotherapy. 1984 Jan; 25(1):16-9. doi: 10.1128/aac.25.1.16. [PMID: 6703681]
  • D N Williams, R B Gustilo, R Beverly, A C Kind. Bone and serum concentrations of five cephalosporin drugs. Relevance to prophylaxis and treatment in orthopedic surgery. Clinical orthopaedics and related research. 1983 Oct; ?(179):253-65. doi: NULL. [PMID: 6617025]
  • M C Thirumoorthi, J A Buckley, C V Vincent, D Kobos, A S Dajani. Efficacy and safety of ceforanide in the treatment of childhood infections. Pediatric infectious disease. 1983 Sep; 2(5):377-80. doi: 10.1097/00006454-198309000-00010. [PMID: 6634466]
  • W J Cady, B G Wulf, M T O'Neil, D W Burney, W R Hamsa. Ceforanide vs. cephalothin concentrations in total joint arthroplasty. Drug intelligence & clinical pharmacy. 1983 Sep; 17(9):645-8. doi: 10.1177/106002808301700910. [PMID: 6617484]
  • W Karney, R Correa-Coronas, R Zajtchuk, J Schwartz, L P Smith, E Tramont. Comparison of cephalothin and ceforanide prophylaxis in cardiac surgery with cardiopulmonary bypass. Antimicrobial agents and chemotherapy. 1983 Jul; 24(1):85-8. doi: 10.1128/aac.24.1.85. [PMID: 6354078]
  • D E Kenady, M D Ram. Biliary levels of ceforanide. Antimicrobial agents and chemotherapy. 1983 May; 23(5):706-9. doi: 10.1128/aac.23.5.706. [PMID: 6870219]
  • S L Barriere, J Mills. Ceforanide: antibacterial activity, pharmacology, and clinical efficacy. Pharmacotherapy. 1982 Nov; 2(6):322-7. doi: 10.1002/j.1875-9114.1982.tb03208.x. [PMID: 6762529]
  • T A Raab, S Balderman, J Bhayana, K Bingham, J Mylotte, T R Beam. A comparison of the safety, efficacy, and distribution of ceforanide and cephalothin in coronary artery bypass graft surgery. The Annals of thoracic surgery. 1982 Apr; 33(4):340-4. doi: 10.1016/s0003-4975(10)63224-9. [PMID: 7041840]
  • L D Mullany, M A French, C H Nightingale, H B Low, L H Ellison, R Quintiliani. Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery. Antimicrobial agents and chemotherapy. 1982 Mar; 21(3):416-20. doi: 10.1128/aac.21.3.416. [PMID: 7103445]
  • A S Dajani, M C Thirumoorthi, R E Bawdon, J A Buckley, M Pfeffer, D R Van Harken, R D Smyth. Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents. Antimicrobial agents and chemotherapy. 1982 Feb; 21(2):282-7. doi: 10.1128/aac.21.2.282. [PMID: 7073266]
  • S Ripa, F La Rosa, A Ghezzi, M Prenna, M Pfeffer. Pharmacokinetics of ceforanide. Antimicrobial agents and chemotherapy. 1982 Feb; 21(2):323-6. doi: 10.1128/aac.21.2.323. [PMID: 7073268]
  • R J Wallace, R R Martin, F J Quinones, S B Greenberg. Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial. Antimicrobial agents and chemotherapy. 1981 Nov; 20(5):648-52. doi: 10.1128/aac.20.5.648. [PMID: 7034641]
  • S S Hawkins, R H Alford, W J Stone, R D Smyth, M Pfeffer. Ceforanide kinetics in renal insufficiency. Clinical pharmacology and therapeutics. 1981 Oct; 30(4):468-74. doi: 10.1038/clpt.1981.190. [PMID: 7285481]
  • J F Jovanovich, L D Saravolatz, K Burch, D J Pohlod. Failure of probenecid to alter the pharmacokinetics of ceforanide. Antimicrobial agents and chemotherapy. 1981 Oct; 20(4):530-2. doi: 10.1128/aac.20.4.530. [PMID: 7342878]
  • E H Estey, S S Weaver, B M LeBlanc, N Brown, D H Ho, G P Bodey. Ceforanide kinetics. Clinical pharmacology and therapeutics. 1981 Sep; 30(3):396-403. doi: NULL. [PMID: 7273604]
  • F H Lee, R D Smyth, D R Van Harken. Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats. Antimicrobial agents and chemotherapy. 1981 Apr; 19(4):625-7. doi: 10.1128/aac.19.4.625. [PMID: 7247385]
  • K A Joiner, B R Lowe, J L Dzink, J G Bartlett. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. The Journal of infectious diseases. 1981 Mar; 143(3):487-94. doi: 10.1093/infdis/143.3.487. [PMID: 6453169]
  • J Carrizosa, W D Kobasa, D Kaye. Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits. Antimicrobial agents and chemotherapy. 1980 Oct; 18(4):562-5. doi: 10.1128/aac.18.4.562. [PMID: 7447418]
  • M Pfeffer, R C Gaver, D R Van Harken. Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide. Journal of pharmaceutical sciences. 1980 Apr; 69(4):398-403. doi: 10.1002/jps.2600690409. [PMID: 7373533]
  • F H Lee, M Pfeffer, D R Van Harken, R D Smyth, G H Hottendorf. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrobial agents and chemotherapy. 1980 Feb; 17(2):188-92. doi: 10.1128/aac.17.2.188. [PMID: 7387141]
  • J R Hess, S J Berman, W H Boughton, J G Sugihara, J E Musgrave, E G Wong, A M Siemsen. Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis. Antimicrobial agents and chemotherapy. 1980 Feb; 17(2):251-3. doi: 10.1128/aac.17.2.251. [PMID: 7387145]
  • R D Smyth, M Pfeffer, A Glick, D R Van Harken, G H Hottendorf. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrobial agents and chemotherapy. 1979 Nov; 16(5):615-21. doi: 10.1128/aac.16.5.615. [PMID: 526003]
  • K H Burch, D Pohlod, L D Saravolatz, T Madhavan, D Kiani, E L Quinn, R Del Busto, J Cardenas, E J Fisher. Ceforanide: in vitro and clinical evaluation. Antimicrobial agents and chemotherapy. 1979 Sep; 16(3):386-91. doi: 10.1128/aac.16.3.386. [PMID: 507795]
  • J A Randolph, R E Buck, K E Price, F Leitner. Comparative bactericidal effect of ceforanide (BL-S 786) and five other cephalosporins in an in vitro pharmacokinetic model. The Journal of antibiotics. 1979 Jul; 32(7):727-33. doi: 10.7164/antibiotics.32.727. [PMID: 396292]
  • R J Wallace, R R Martin, S B Greenberg. Ceforanide (BL-S786) in the treatment of community-acquired bacterial pneumonia. Infection. 1979; 7(4):176-9. doi: 10.1007/bf01640937. [PMID: 315929]
  • A Tourian. Control of phenylalanine hydroxylase synthesis in tissue culture by serum and insulin. Journal of cellular physiology. 1976 Jan; 87(1):15-24. doi: 10.1002/jcp.1040870104. [PMID: 1401]